运营费用 - 公司2024年第三季度末的一般和管理费用为166.2万美元较2023年同期的79.3万美元增长110%主要受人员薪酬福利等因素影响[123] - 公司2024年第三季度末的研发费用为117.4万美元较2023年同期的47.1万美元增长149%主要归因于临床试验和产品开发成本[123] - 公司2024年第三季度末的权证费用 - 终止协议为0较2023年同期的455.6万美元减少100%[123] - 公司2024年第三季度末的总运营费用为283.6万美元较2023年同期的582.0万美元减少51%[123] - 公司2024年上半年末的一般和管理费用为346.1万美元较2023年同期的129.5万美元增长167%[124] - 公司2024年上半年末的研发费用为212.8万美元较2023年同期的83.9万美元增长154%[124] - 公司2024年上半年末的权证费用 - 终止协议为0较2023年同期的455.6万美元减少100%[124] - 公司2024年上半年末的总运营费用为558.9万美元较2023年同期的669.0万美元减少16%[124] 利息收支 - 2024年第三季度和上半年利息支出均低于10万美元与债务折扣摊销有关2023年同期无此费用[128] - 2024年第三季度利息收入低于10万美元上半年为20万美元2023年同期均低于10万美元[129] 现金与运营支撑 - 2024年9月30日现金为520万美元营运资金为410万美元[131] - 估计当前现金资源可支撑运营至2025年第二季度[131] 融资需求 - 需约4000万美元额外融资用于首个适应症商业化运营[133] 现金流量 - 2024年上半年经营活动净现金使用340万美元[134] - 2024年上半年投资活动净现金使用5000美元[135] - 2024年上半年融资活动净现金提供为0[135] - 2023年上半年融资活动净现金提供310万美元[136] 员工离职福利 - 关键员工离职相关福利为110万到160万美元[137] 表外安排 - 无表外安排[138] 会计政策 - 会计政策按美国公认会计原则编制并定期重估调整[139]

Access the Virtual Investor "What This Means" Segment here THE WOODLANDS, TX, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nervetargeted treatments, today announced that it recently participated in a Virtual Investor "What This Means" segment. For the segment, Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discussed the Company's recently announced 4-6 week positive follow-up data, f ...

Autonomix Medical, Inc. (AMIX) shared positive preliminary results from its first five lead-in patients in a proof-of-concept trial. The trial assesses the safety and effectiveness of Autonomix's proprietary radiofrequency (RF) ablation technology, designed to ablate targeted nerves and reduce pain in late-stage pancreatic cancer patients. Among participants, three treated through femoral access experienced significant pain reduction — from a mean score of 8 to 1.33 on the Visual Analog Scale — and were abl ...

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 points on Monday.The Dow traded up 0.52% to 42,333.84 while the NASDAQ rose 0.43% to 18,598.02. The S&P 500 also rose, gaining, 0.31% to 5,826.12.Check This Out: How To Earn $500 A Month From Ford Stock Ahead Of Q3 EarningsLeading and Lagging SectorsUtilities shares rose by 1.1% on Monday.In trading on Monday, energy shares fell by 1%.Top HeadlineON Semiconductor Corp ON posted better-than-expected earnings for ...

Autonomix Medical, Inc. AMIX stock is trading higher on Monday, with a strong session volume of 6.11 million compared to the average volume of 22.87 thousand, as per data from Benzinga Pro. The nano-cap firm focused on developing technologies for the nervous system revealed preliminary results from the first five "lead-in" patients in the company's ongoing proof-of-concept human trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigat ...

THE WOODLANDS, TX, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nervetargeted treatments, today announced that it will release a Virtual Investor "What This Means" segment on Wednesday, October 30, 2024. For the segment, Dr. Robert Schwartz, Chief Medical Officer of Autonomix will discuss additional findings from the 4-6 week follow-up data from the first five "lead-in" patients in the Company ...

THE WOODLANDS, TX, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of its common stock. The reverse stock split will take effect at 11:59 pm (Eastern Time) on October 24, 2024, a ...

Live webcast fireside chat on Tuesday, October 15th at 2:30 PM ET THE WOODLANDS, TX, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Brad Hauser, CEO of Autonomix, will participate in a fireside chat at the 2024 Healthcare Virtual Summit, presented by Maxim Group LLC on October ...

THE WOODLANDS, TX, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nervetargeted treatments, today announced it has been selected for a featured podium presentation at the 2024 Octane Medical Innovation Forum taking place on October 8-9, 2024 in Irvine, California. The Octane Medical Innovation Forum brings together industry experts, entrepreneurs, investors and thought leaders for two days of l ...

Presentation to discuss latest developments in future AI applications in interventional radiology, specifically highlighting the early results from the Company's ongoing proof-of-concept (PoC) human clinical trial THE WOODLANDS, TX, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nervetargeted treatments, today announced its technology and interim clinical trial findings will be featured in a pod ...